메뉴 건너뛰기




Volumn 40, Issue 5, 2012, Pages 1688-1707

Absence of clinically relevant interactions between rivaroxaban–an oral, direct factor xa inhibitor–and digoxin or atorvastatin in healthy subjects

Author keywords

Atorvastatin; Digoxin; Drug interactions; Pharmacodynamics; Pharmacokinetics; Rivaroxaban

Indexed keywords

ATORVASTATIN; BLOOD CLOTTING FACTOR 10A; CREATINE KINASE; DIGOXIN; GLUTAMATE DEHYDROGENASE; RIVAROXABAN; ANTIARRHYTHMIC AGENT; FIBRINOLYTIC AGENT; HEPTANOIC ACID DERIVATIVE; MORPHOLINE DERIVATIVE; PYRROLE DERIVATIVE; THIOPHENE DERIVATIVE;

EID: 84880594628     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/030006051204000508     Document Type: Article
Times cited : (52)

References (40)
  • 1
    • 79551638273 scopus 로고    scopus 로고
    • Novel oral Factor Xa and thrombin inhibitors in the management of thromboembolism
    • Eriksson BI, Quinlan DJ, Eikelboom JW: Novel oral Factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med 2011; 62: 41-57.
    • (2011) Annu Rev Med , vol.62 , pp. 41-57
    • Eriksson, B.I.1    Quinlan, D.J.2    Eikelboom, J.W.3
  • 2
    • 45949099359 scopus 로고    scopus 로고
    • Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
    • Eriksson BI, Borris LC, Friedman RJ, et al: Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
    • (2008) N Engl J Med , vol.358 , pp. 2765-2775
    • Eriksson, B.I.1    Borris, L.C.2    Friedman, R.J.3
  • 3
    • 46049106502 scopus 로고    scopus 로고
    • Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial
    • Kakkar AK, Brenner B, Dahl OE, et al: Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-39.
    • (2008) Lancet , vol.372 , pp. 31-39
    • Kakkar, A.K.1    Brenner, B.2    Dahl, O.E.3
  • 4
    • 45949103416 scopus 로고    scopus 로고
    • Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
    • Lassen MR, Ageno W, Borris LC, et al: Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
    • (2008) N Engl J Med , vol.358 , pp. 2776-2786
    • Lassen, M.R.1    Ageno, W.2    Borris, L.C.3
  • 5
    • 65549169515 scopus 로고    scopus 로고
    • Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial
    • Turpie AGG, Lassen MR, Davidson BL, et al: Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673-1680.
    • (2009) Lancet , vol.373 , pp. 1673-1680
    • Turpie, A.1    Lassen, M.R.2    Davidson, B.L.3
  • 6
    • 80052592404 scopus 로고    scopus 로고
    • Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
    • Patel MR, Mahaffey KW, Garg J, et al: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
    • (2011) N Engl J Med , vol.365 , pp. 883-891
    • Patel, M.R.1    Mahaffey, K.W.2    Garg, J.3
  • 7
    • 78650619315 scopus 로고    scopus 로고
    • Oral rivaroxaban for symptomatic venous thromboembolism
    • The EINSTEIN Investigators: Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
    • (2010) N Engl J Med , vol.363 , pp. 2499-2510
  • 8
    • 84859385808 scopus 로고    scopus 로고
    • Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
    • The EINSTEIN–PE Investigators: Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
    • (2012) N Engl J Med , vol.366 , pp. 1287-1297
  • 9
    • 84862907587 scopus 로고    scopus 로고
    • Rivaroxaban in patients with a recent acute coronary syndrome
    • Mega JL, Braunwald E, Wiviott SD, et al: Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19.
    • (2012) N Engl J Med , vol.366 , pp. 9-19
    • Mega, J.L.1    Braunwald, E.2    Wiviott, S.D.3
  • 10
    • 3042520870 scopus 로고    scopus 로고
    • Digoxin in the management of cardiovascular disorders
    • Gheorghiade M, Adams KF, Jr, Colucci WS: Digoxin in the management of cardiovascular disorders. Circulation 2004; 109: 2959-2964.
    • (2004) Circulation , vol.109 , pp. 2959-2964
    • Gheorghiade, M.1    Adams, K.F.2    Colucci, W.S.3
  • 11
    • 0025779484 scopus 로고
    • Atrial fibrillation as an independent risk factor for stroke: The Framingham Study
    • Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-988.
    • (1991) Stroke , vol.22 , pp. 983-988
    • Wolf, P.A.1    Abbott, R.D.2    Kannel, W.B.3
  • 12
    • 0033514320 scopus 로고    scopus 로고
    • Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine
    • Fromm MF, Kim RB, Stein CM, et al: Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999; 99: 552-557.
    • (1999) Circulation , vol.99 , pp. 552-557
    • Fromm, M.F.1    Kim, R.B.2    Stein, C.M.3
  • 13
    • 0024102997 scopus 로고
    • Pharmacokinetic interactions with digoxin
    • Rodin SM, Johnson BF: Pharmacokinetic interactions with digoxin. Clin Pharmacokinet 1988; 15: 227-244.
    • (1988) Clin Pharmacokinet , vol.15 , pp. 227-244
    • Rodin, S.M.1    Johnson, B.F.2
  • 14
    • 33646553591 scopus 로고    scopus 로고
    • The safety of digoxin as a pharmacological treatment of atrial fibrillation
    • Tamargo J, Delpon E, Caballero R: The safety of digoxin as a pharmacological treatment of atrial fibrillation. Expert Opin Drug Saf 2006; 5: 453-467.
    • (2006) Expert Opin Drug Saf , vol.5 , pp. 453-467
    • Tamargo, J.1    Delpon, E.2    Caballero, R.3
  • 15
    • 39049156419 scopus 로고    scopus 로고
    • Potential use of statins to prevent atrial fibrillation after coronary artery bypass surgery
    • Howard PA, Barnes BJ: Potential use of statins to prevent atrial fibrillation after coronary artery bypass surgery. Ann Pharmacother 2008; 42: 253-258.
    • (2008) Ann Pharmacother , vol.42 , pp. 253-258
    • Howard, P.A.1    Barnes, B.J.2
  • 16
    • 38849099077 scopus 로고    scopus 로고
    • Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery
    • Lertsburapa K, White CM, Kluger J, et al: Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery. J Thorac Cardiovasc Surg 2008; 135: 405-411.
    • (2008) J Thorac Cardiovasc Surg , vol.135 , pp. 405-411
    • Lertsburapa, K.1    White, C.M.2    Kluger, J.3
  • 17
    • 33749505716 scopus 로고    scopus 로고
    • Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study
    • Patti G, Chello M, Candura D, et al: Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006; 114: 1455-1461.
    • (2006) Circulation , vol.114 , pp. 1455-1461
    • Patti, G.1    Chello, M.2    Candura, D.3
  • 18
    • 0242383181 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of atorvastatin
    • Lennernäs H: Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003; 42: 1141-1160.
    • (2003) Clin Pharmacokinet , vol.42 , pp. 1141-1160
    • Lennernäs, H.1
  • 19
    • 2942705774 scopus 로고    scopus 로고
    • Safety of statins: Focus on clinical pharmacokinetics and drug interactions
    • Bellosta S, Paoletti R, Corsini A: Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109(23 suppl 1): III50-III57.
    • (2004) Circulation , vol.109 , Issue.23 , pp. III50-III57
    • Bellosta, S.1    Paoletti, R.2    Corsini, A.3
  • 20
    • 0034821958 scopus 로고    scopus 로고
    • Rhabdomyolysis and HMG-CoA reductase inhibitors
    • Omar MA, Wilson JP, Cox TS: Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35: 1096-1107.
    • (2001) Ann Pharmacother , vol.35 , pp. 1096-1107
    • Omar, M.A.1    Wilson, J.P.2    Cox, T.S.3
  • 21
    • 0036163750 scopus 로고    scopus 로고
    • FDA adverse event reports on statin-associated rhabdomyolysis
    • Omar MA, Wilson JP: FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002; 36: 288-295.
    • (2002) Ann Pharmacother , vol.36 , pp. 288-295
    • Omar, M.A.1    Wilson, J.P.2
  • 22
    • 22844442726 scopus 로고    scopus 로고
    • In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 − an oral, direct Factor Xa inhibitor
    • Perzborn E, Strassburger J, Wilmen A, et al: In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 − an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3: 514-521.
    • (2005) J Thromb Haemost , vol.3 , pp. 514-521
    • Perzborn, E.1    Strassburger, J.2    Wilmen, A.3
  • 23
    • 78650827771 scopus 로고    scopus 로고
    • The discovery and development of rivaroxaban, an oral, direct Factor Xa inhibitor
    • Perzborn E, Roehrig S, Straub A, et al: The discovery and development of rivaroxaban, an oral, direct Factor Xa inhibitor. Nat Rev Drug Discov 2011; 10: 61-75.
    • (2011) Nat Rev Drug Discov , vol.10 , pp. 61-75
    • Perzborn, E.1    Roehrig, S.2    Straub, A.3
  • 24
    • 25844525489 scopus 로고    scopus 로고
    • Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor
    • Kubitza D, Becka M, Voith B, et al: Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412-421.
    • (2005) Clin Pharmacol Ther , vol.78 , pp. 412-421
    • Kubitza, D.1    Becka, M.2    Voith, B.3
  • 25
    • 29144518504 scopus 로고    scopus 로고
    • Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects
    • Kubitza D, Becka M, Wensing G, et al: Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873-880.
    • (2005) Eur J Clin Pharmacol , vol.61 , pp. 873-880
    • Kubitza, D.1    Becka, M.2    Wensing, G.3
  • 26
    • 66449099711 scopus 로고    scopus 로고
    • Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans
    • Weinz C, Schwarz T, Kubitza D, et al: Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans. Drug Metab Dispos 2009; 37: 1056-1064.
    • (2009) Drug Metab Dispos , vol.37 , pp. 1056-1064
    • Weinz, C.1    Schwarz, T.2    Kubitza, D.3
  • 28
    • 0032848316 scopus 로고    scopus 로고
    • Pglycoprotein system as a determinant of drug interactions: The case of digoxin-verapamil
    • Verschraagen M, Koks CH, Schellens JH, et al: Pglycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol Res 1999; 40: 301-306.
    • (1999) Pharmacol Res , vol.40 , pp. 301-306
    • Verschraagen, M.1    Koks, C.H.2    Schellens, J.H.3
  • 29
    • 0031925714 scopus 로고    scopus 로고
    • Digoxin revisited
    • Li-Saw-Hee FL, Lip GYH: Digoxin revisited. QJM 1998; 91: 259-264.
    • (1998) QJM , vol.91 , pp. 259-264
    • Li-Saw-Hee, F.L.1    Lip, G.2
  • 30
    • 33846448135 scopus 로고    scopus 로고
    • Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmaco -dynamics of rivaroxaban (BAY 59-7939) in healthy subjects
    • Kubitza D, Becka M, Zuehlsdorf M, et al: Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmaco -dynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007; 47: 218-226.
    • (2007) J Clin Pharmacol , vol.47 , pp. 218-226
    • Kubitza, D.1    Becka, M.2    Zuehlsdorf, M.3
  • 32
    • 77957699729 scopus 로고    scopus 로고
    • Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)
    • Camm AJ, Kirchhof P, Lip GYH, et al: Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
    • (2010) Eur Heart J , vol.31 , pp. 2369-2429
    • Camm, A.J.1    Kirchhof, P.2    Lip, G.3
  • 33
    • 84856745317 scopus 로고    scopus 로고
    • Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians evidence-based clinical practice guidelines
    • You JJ, Singer DE, Howard PA, et al: Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141(2 suppl): e531S-e575S.
    • (2012) Chest , vol.141 , Issue.2 , pp. e531S-e575S
    • You, J.J.1    Singer, D.E.2    Howard, P.A.3
  • 34
    • 34250901454 scopus 로고    scopus 로고
    • Latest medical treatment strategies for venous thrombo -embolism
    • McRae SJ, Eikelboom JW: Latest medical treatment strategies for venous thrombo -embolism. Expert Opin Pharmacother 2007; 8: 1221-1233.
    • (2007) Expert Opin Pharmacother , vol.8 , pp. 1221-1233
    • McRae, S.J.1    Eikelboom, J.W.2
  • 35
    • 79959522836 scopus 로고    scopus 로고
    • In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban
    • Gnoth MJ, Buetehorn U, Muenster U, et al: In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther 2011; 338: 372-380.
    • (2011) J Pharmacol Exp Ther , vol.338 , pp. 372-380
    • Gnoth, M.J.1    Buetehorn, U.2    Muenster, U.3
  • 36
    • 0023189084 scopus 로고
    • Toxic neuropsychiatric effects of digoxin at therapeutic serum concentrations
    • Eisendrath SJ, Sweeney MA: Toxic neuropsychiatric effects of digoxin at therapeutic serum concentrations. Am J Psychiatry 1987; 144: 506-507.
    • (1987) Am J Psychiatry , vol.144 , pp. 506-507
    • Eisendrath, S.J.1    Sweeney, M.A.2
  • 38
    • 3242759673 scopus 로고    scopus 로고
    • No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers
    • Sarich TC, Schützer KM, Wollbratt M, et al: No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers. J Clin Pharmacol 2004; 44: 935-941.
    • (2004) J Clin Pharmacol , vol.44 , pp. 935-941
    • Sarich, T.C.1    Schützer, K.M.2    Wollbratt, M.3
  • 39
    • 3242742755 scopus 로고    scopus 로고
    • No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran
    • Sarich TC, Schützer KM, Dorani H, et al: No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran. J Clin Pharmacol 2004; 44: 928-934.
    • (2004) J Clin Pharmacol , vol.44 , pp. 928-934
    • Sarich, T.C.1    Schützer, K.M.2    Dorani, H.3
  • 40
    • 0036394274 scopus 로고    scopus 로고
    • Absence of interaction of fondaparinux sodium with digoxin in healthy volunteers
    • Mant T, Fournié P, Ollier C, et al: Absence of interaction of fondaparinux sodium with digoxin in healthy volunteers. Clin Pharmacokinet 2002; 41(suppl 2): 39-45.
    • (2002) Clin Pharmacokinet , vol.41 , pp. 39-45
    • Mant, T.1    Fournié, P.2    Ollier, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.